{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:50:47Z","timestamp":1782485447750,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41587-023-01682-2","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T17:03:24Z","timestamp":1678295004000},"page":"314-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rapid-response manufacturing of adenovirus-vectored vaccines"],"prefix":"10.1038","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-8727","authenticated-orcid":false,"given":"Carina C. D.","family":"Joe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiuseppe","family":"Nestola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-7562","authenticated-orcid":false,"given":"Alexander D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"1682_CR1","unstructured":"CEPI. Coalition for Epidemic Preparedness Innovations launches plan to tackle risk of future pandemics and epidemics. https:\/\/cepi.net\/news_cepi\/cepi-launches-plan-to-tackle-risk-of-future-pandemics-and-epidemics\/ (2021)."},{"key":"1682_CR2","unstructured":"Airfinity. AstraZeneca and Pfizer\/BioNTech saved over 12 million lives in the first year of vaccination. https:\/\/www.airfinity.com\/insights\/astrazeneca-and-pfizer-biontech-saved-over-12-million-lives-in-the-first (2022)."},{"key":"1682_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14760584.2022.2092472","volume":"21","author":"S Chuenkitmongkol","year":"2022","unstructured":"Chuenkitmongkol, S. et al. Expert Rev. Vaccines 21, 1255\u20131268 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"1682_CR4","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2214-109X(21)00545-3","volume":"10","author":"K Soboleva","year":"2022","unstructured":"Soboleva, K. et al. Lancet Glob. Health 10, e33\u2013e34 (2022).","journal-title":"Lancet Glob. Health"},{"key":"1682_CR5","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.3346\/jkms.2021.36.e197","volume":"12","author":"K Huh","year":"2021","unstructured":"Huh, K. et al. J. Korean Med. Sci. 12, e197 (2021).","journal-title":"J. Korean Med. Sci."},{"key":"1682_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/bit.27945","volume":"119","author":"CCD Joe","year":"2022","unstructured":"Joe, C. C. D. et al. Biotechnol. Bioeng. 119, 48\u201358 (2022).","journal-title":"Biotechnol. Bioeng."},{"key":"1682_CR7","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/vaccines9111249","volume":"9","author":"A Berg","year":"2021","unstructured":"Berg, A. et al. Vaccines (Basel) 9, 1249 (2021).","journal-title":"Vaccines (Basel)"},{"key":"1682_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1682_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/vaccines9010003","volume":"9","author":"Z Kis","year":"2020","unstructured":"Kis, Z., Kontoravdi, C., Shattock, R. & Shah, N. Vaccines (Basel) 9, 3 (2020).","journal-title":"Vaccines (Basel)"},{"key":"1682_CR10","doi-asserted-by":"publisher","unstructured":"Joe, C. C. D. et al. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.12.22.473478 (2021).","DOI":"10.1101\/2021.12.22.473478"},{"key":"1682_CR11","unstructured":"Reuters. IMF sees cost of COVID pandemic rising beyond $12.5 trillion estimate. https:\/\/www.reuters.com\/business\/imf-sees-cost-covid-pandemic-rising-beyond-125-trillion-estimate-2022-01-20\/ (2022)."},{"key":"1682_CR12","unstructured":"Mishra, M. World to spend $157 billion on COVID-19 vaccines through 2025-report. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/world-spend-157-billion-covid-19-vaccines-through-2025-report-2021-04-29\/ (2021)."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01682-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T17:15:33Z","timestamp":1678900533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01682-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1038\/s41587-023-01682-2","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"8 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C.D.J. and A.D.D. are named inventors or contributors to intellectual property assigned to Oxford University Innovation relating to the ChAdOx1 nCoV-19 vaccine manufacturing process and will receive a proportion of proceeds from out-licensing of the intellectual property. A.D.D. has received research and consultancy income from AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}